Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Hepatic enzyme increased? 6,778 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 6,778 reports of Hepatic enzyme increased have been filed in association with INFLIXIMAB (Renflexis). This represents 4.8% of all adverse event reports for INFLIXIMAB.

6,778
Reports of Hepatic enzyme increased with INFLIXIMAB
4.8%
of all INFLIXIMAB reports
1,883
Deaths
2,546
Hospitalizations

How Dangerous Is Hepatic enzyme increased From INFLIXIMAB?

Of the 6,778 reports, 1,883 (27.8%) resulted in death, 2,546 (37.6%) required hospitalization, and 2,037 (30.1%) were considered life-threatening.

Is Hepatic enzyme increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 6,778 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Hepatic enzyme increased?

METHOTREXATE (9,857) ADALIMUMAB (8,693) TOCILIZUMAB (7,691) ETANERCEPT (7,481) ABATACEPT (7,397) RITUXIMAB (7,247) LEFLUNOMIDE (7,173) HYDROXYCHLOROQUINE (6,555) TOFACITINIB (6,269) PREDNISONE (5,897)

Which INFLIXIMAB Alternatives Have Lower Hepatic enzyme increased Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Hepatic enzyme increased Reports All Drugs Causing Hepatic enzyme increased INFLIXIMAB Demographics